Stock Track | Relay Therapeutics Plunges 25% as $200 Million Share Offering Sparks Dilution Fears

Stock Track09-12

Shares of Relay Therapeutics (RLAY) plummeted by over 25% in pre-market trading on Tuesday, September 11th, after the clinical-stage precision medicine company announced a $200 million public offering of its common stock.

On Monday evening, Relay revealed plans to sell 28.57 million shares at $7.00 per share, a significant discount to its previous closing price of $9.00. The offering grants underwriters a 30-day option to purchase an additional 4.29 million shares and is expected to close on or around September 12th.

The move to raise additional capital through a dilutive stock offering has sparked concerns among investors about the potential dilution of their existing stakes in the company. Share dilution typically puts downward pressure on a company's stock price in the near term, as it increases the total number of outstanding shares and reduces the ownership percentage of existing shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment